CClinicalTrials.gg
CompletedNCT05868187CRFUpdated Dec 9, 2024

CanRestoreFunction Cancer-related Fatigue ( CRF )

An interventional study of Exercise, Problem-Solving Session and Education in Breast Neoplasm, sponsored by University of Cincinnati. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by University of Cincinnati · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The goal of this randomized control trial is to determine if participating in an 8-week online cancer-related fatigue management intervention consisting of individualized exercise program, one-on-one goal setting and action plan development and interactive educational module will significantly reduce the perception of cancer-related fatigue, improve the quality of life, improve perceived cognition, and perceived function of breast cancer compared to a wait-list control group. The aim the project is to determine if an online cancerrelated fatigue management program is associated with 1. A decrease in cancer-related fatigue. 2. An improved perception of their ability and satisfaction in completing important activities 3. Greater quality of life. 4. Improved mobility 5. Improved perceived cognition

02

Conditions studied

  • Breast Neoplasm

Keywords

  • cancer-related fatigue
  • breast cancer
  • exercise
  • problem-solving
  • online interactive education
03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's enrollment of 47 is below the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

University of Cincinnati is the lead sponsor of 314 studies on the registry; 43 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • been diagnosed with any type of cancer within 5 years of enrollment,
  • received chemotherapy and/or radiation therapy
  • have access to mobile device or computer
  • have basic computer or mobile device skills,
  • have a significant level of fatigue defined as >3 on 0-10 scale using the Oneitem Fatigue Scale

Exclusion criteria

Exclusion Criteria:

  • have metastatic cancer (Stage 4),
  • do not have a signed medical release by their physician or physician extender indicating that the participant can safely participate in the exercise program,
  • chronic fatigue prior to cancer diagnosis, such as fibromyalgia
  • are unable to follow verbal or written assessment instructions, are non-English speaking
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Exercise, Problem-Solving and Education

    Individualized exercise program Weekly Goals setting and problem-solving session to create a weekly action plan Four Assigned interactive educational modules

    Behavioral: Exercise, Problem-Solving Session and Education

  • No intervention
    Usual Care

    Participants will complete their daily routines as they typically do.

Interventions

  • BehavioralExercise, Problem-Solving Session and Education

    Complete assigned exercises three times a week Complete Action plan co-developed Complete part or all of one of the four interactive educational modules

06

What researchers measure

Primary outcomes

  1. Brief Fatigue Inventory

    This 9-item scale assesses the severity and interference of fatigue based on a 0 (no fatigue) to 10 (greatest fatigue) scale

    Time frame: Baseline

  2. Brief Fatigue Inventory

    This 9-item scale assesses the severity and interference of fatigue based on a 0 (no fatigue) to 10 (greatest fatigue) scale

    Time frame: 4-week

  3. Brief Fatigue Inventory

    This 9-item scale assesses the severity and interference of fatigue based on a 0 (no fatigue) to 10 (greatest fatigue) scale

    Time frame: 8-week

Secondary outcomes

  1. Canadian Occupational Performance Measure

    The OT administers the COPM, which is a semi-structured interview to understand the routine activities that the participant completes daily, specifically their self-care, leisure, and social activities. The participant rates the importance of each of the activities using a 0 to 10 scale. Zero indicates "no importance" and 10 indicates "very important." Then the participant separately rates their perception of how well they currently perform each of the important activities and how satisfied they are with their performance using a 0 to 10 scale. Zero indicates that "they are not able to perform" or "they are not satisfied" and 10 indicates that "they are able to perform the activity well" or "they are very satisfied."

    Time frame: Baseline

  2. Canadian Occupational Performance Measure

    The OT administers the COPM, which is a semi-structured interview to understand the routine activities that the participant completes daily, specifically their self-care, leisure, and social activities. The participant rates the importance of each of the activities using a 0 to 10 scale. Zero indicates "no importance" and 10 indicates "very important." Then the participant separately rates their perception of how well they currently perform each of the important activities and how satisfied they are with their performance using a 0 to 10 scale. Zero indicates that "they are not able to perform" or "they are not satisfied" and 10 indicates that "they are able to perform the activity well" or "they are very satisfied."

    Time frame: 4-week

  3. Canadian Occupational Performance Measure

    The OT administers the COPM, which is a semi-structured interview to understand the routine activities that the participant completes daily, specifically their self-care, leisure, and social activities. The participant rates the importance of each of the activities using a 0 to 10 scale. Zero indicates "no importance" and 10 indicates "very important." Then the participant separately rates their perception of how well they currently perform each of the important activities and how satisfied they are with their performance using a 0 to 10 scale. Zero indicates that "they are not able to perform" or "they are not satisfied" and 10 indicates that "they are able to perform the activity well" or "they are very satisfied."

    Time frame: 8-week

  4. Functional Assessment of Chronic Illness Therapy-Fatigue

    This 40-item 5-point Likert scale (0=Not at all 1=A little bit 2=Somewhat 3= Quite a bit 4=Very much) evaluates quality of life in individuals with fatigue as measured in 5 domains: physical, social/family, emotional, functional well-being, and fatigue. Higher scores reflect greater quality of life

    Time frame: Baseline

  5. Functional Assessment of Chronic Illness Therapy-Fatigue

    This 40-item 5-point Likert scale (0=Not at all 1=A little bit 2=Somewhat 3= Quite a bit 4=Very much) evaluates quality of life in individuals with fatigue as measured in 5 domains: physical, social/family, emotional, functional well-being, and fatigue. Higher scores reflect greater quality of life

    Time frame: 4-weeks

  6. Functional Assessment of Chronic Illness Therapy-Fatigue

    This 40-item 5-point Likert scale (0=Not at all 1=A little bit 2=Somewhat 3= Quite a bit 4=Very much) evaluates quality of life in individuals with fatigue as measured in 5 domains: physical, social/family, emotional, functional well-being, and fatigue. Higher scores reflect greater quality of life

    Time frame: 8-weeks

  7. PROMIS Cognitive Function Ability 8a

    This 8-item 5-point Likert scale \[Never, Rarely (Once) Sometimes (Two or three times) Often (About once a day) Very often (Several times a day)\] evaluates patient-perceived cognitive abilities, its interference with daily functioning, whether other people observe cognitive impairments, and its impact on quality of life

    Time frame: Baseline

  8. PROMIS Cognitive Function Ability 8a

    This 8-item 5-point Likert scale \[Never, Rarely (Once) Sometimes (Two or three times) Often (About once a day) Very often (Several times a day)\] evaluates patient-perceived cognitive abilities, its interference with daily functioning, whether other people observe cognitive impairments, and its impact on quality of life

    Time frame: 4-weeks

  9. PROMIS Cognitive Function Ability 8a

    This 8-item 5-point Likert scale \[Never, Rarely (Once) Sometimes (Two or three times) Often (About once a day) Very often (Several times a day)\] evaluates patient-perceived cognitive abilities, its interference with daily functioning, whether other people observe cognitive impairments, and its impact on quality of life

    Time frame: 8-weeks

  10. Promis Applied Cognitive Abilities 8a

    This 8-item 5-point Likert scale \[Not at all A little bit, Somewhat, Quite a bit, Very much\] evaluates the patient-perceived cognitive deficits

    Time frame: Baseline

  11. Promis Applied Cognitive Abilities 8a

    This 8-item 5-point Likert scale \[Not at all A little bit, Somewhat, Quite a bit, Very much\] evaluates the patient-perceived cognitive deficits

    Time frame: 4-weeks

  12. Promis Applied Cognitive Abilities 8a

    This 8-item 5-point Likert scale \[Not at all A little bit, Somewhat, Quite a bit, Very much\] evaluates the patient-perceived cognitive deficits

    Time frame: 8-weeks

  13. 6-minute walk test

    Participants completes a 6-minute walk at their chosen pace and with permitted standing rest breaks

    Time frame: Baseline

  14. 6-minute walk test

    Participants completes a 6-minute walk at their chosen pace and with permitted standing rest breaks

    Time frame: 4-weeks

  15. 6-minute walk test

    Participants completes a 6-minute walk at their chosen pace and with permitted standing rest breaks

    Time frame: 8-weeks

  16. 30 second sit to stand

    Participants are seated in a standard height fixed chair without armrests, which is placed against a wall. They will move from sitting to standing and back to sitting position, with arms crossed against chest. The number of complete stands and sits

    Time frame: Baseline

  17. 30 second sit to stand

    Participants are seated in a standard height fixed chair without armrests, which is placed against a wall. They will move from sitting to standing and back to sitting position, with arms crossed against chest. The number of complete stands and sits

    Time frame: 4-weeks

  18. 30 second sit to stand

    Participants are seated in a standard height fixed chair without armrests, which is placed against a wall. They will move from sitting to standing and back to sitting position, with arms crossed against chest. The number of complete stands and sits

    Time frame: 8-weeks

  19. Average number of steps

    Fitbit will track the number of steps that the participants takes each day

    Time frame: Week 1

  20. Average number of steps

    Fitbit will track the number of steps that the participants takes each day

    Time frame: Week 2

  21. Average number of steps

    Fitbit will track the number of steps that the participants takes each day

    Time frame: Week 3

  22. Average number of steps

    Fitbit will track the number of steps that the participants takes each day

    Time frame: Week 4

  23. Average number of steps

    Fitbit will track the number of steps that the participants takes each day

    Time frame: Week 5

  24. Average number of steps

    Fitbit will track the number of steps that the participants takes each day

    Time frame: Week 6

  25. Average number of steps

    Fitbit will track the number of steps that the participants takes each day

    Time frame: Week 7

  26. Average number of steps

    Fitbit will track the number of steps that the participants takes each day

    Time frame: Week 8

  27. Average heart rate

    Fitbit will track daily heart rate of each participant

    Time frame: Week 1

  28. Average heart rate

    Fitbit will track daily heart rate of each participant

    Time frame: Week 2

  29. Average heart rate

    Fitbit will track daily heart rate of each participant

    Time frame: Week 3

  30. Average heart rate

    Fitbit will track daily heart rate of each participant

    Time frame: Week 4

  31. Average heart rate

    Fitbit will track daily heart rate of each participant

    Time frame: Week 5

  32. Average heart rate

    Fitbit will track daily heart rate of each participant

    Time frame: Week 6

  33. Average heart rate

    Fitbit will track daily heart rate of each participant

    Time frame: Week 7

  34. Average heart rate

    Fitbit will track daily heart rate of each participant

    Time frame: Week 8

07

Study locations

1 site
  • University of Cincinnati
    Cincinnati, Ohio 45221, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05868187
Lead sponsor
University of Cincinnati
Collaborators
University of Dayton
Responsible party
Anne Fleischer (Associate Professor, University of Cincinnati) — Principal investigator
First posted
May 22, 2023
Start date
Mar 1, 2023
Primary completion
Aug 1, 2024
Completion
Aug 1, 2024
Last update
Dec 9, 2024

Study contacts

Anne Fleischer, Ph.D
principal investigator · University of Cincinnati

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion